BioCentury
ARTICLE | Management Tracks

Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more

November 3, 2020 2:03 AM UTC

Gene therapy developer Freeline Therapeutics Holdings plc (NASDAQ:FRLN) hired Mark Baldry as chief commercial officer. He previously held the same role at Wave Life Sciences Ltd. (NASDAQ:WVE). 

Rare disease play X4 Pharmaceuticals Inc. (NASDAQ:XFOR) appointed Art Taveras as CSO. He was CSO of Comet Therapeutics Inc. ...